Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MeVis Medical Solutions AGFRA:M3V 69 3-Year EBITDA Growth Rate is -24.50% as of Mar. 2026. GuruFocus rates FRA:M3V with a GF Score™ of 69/100 and a GF Value™ of €22.29 (Fairly Valued). The stock has 5 warning signs investors should review. Among 524 Healthcare Providers & Services companies, MeVis Medical Solutions AG ranks worse than 90.27% on this metric.
During the past 12 months, MeVis Medical Solutions AG's average EBITDA Per Share Growth Rate was -58.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -24.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -8.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -6.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of MeVis Medical Solutions AG was 23.70% per year. The lowest was -32.00% per year. And the median was 2.30% per year.
MeVis Medical Solutions AG (FRA:M3V) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
MeVis Medical Solutions AG 3-Year EBITDA Growth Rate Related Terms
FRA:M3V vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, MeVis Medical Solutions AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeVis Medical Solutions AG 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where MeVis Medical Solutions AG's 3-Year EBITDA Growth Rate falls into.
MeVis Medical Solutions AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -24.50% mean?
MeVis Medical Solutions AG (FRA:M3V) has a 3-Year EBITDA Growth Rate of -24.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MeVis Medical Solutions AG and its competitors. According to the industry distribution chart, MeVis Medical Solutions AG ranks #473 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 90.3%.
Is MeVis Medical Solutions AG's 3-Year EBITDA Growth Rate too high?
MeVis Medical Solutions AG's current 3-Year EBITDA Growth Rate is -24.50%. Based on the distribution chart, MeVis Medical Solutions AG ranks #473 out of 524 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, MeVis Medical Solutions AG has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MeVis Medical Solutions AG ranks #473 out of 524 companies for 3-Year EBITDA Growth Rate. This places MeVis Medical Solutions AG in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.80, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MeVis Medical Solutions AG and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeVis Medical Solutions AG's current 3-Year EBITDA Growth Rate is -24.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
Based on GuruFocus' analysis, MeVis Medical Solutions AG (FRA:M3V) is currently considered Fairly Valued. The stock's GF Value™ is €22.29, compared to a current price of €23.80 — trading 6.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -24.50%. MeVis Medical Solutions AG's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current 3-Year EBITDA Growth Rate is -24.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?
Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued.
The current stock price of €23.80 is trading 6.8% above its estimated GF Value™ of €22.29.
GuruFocus considers MeVis Medical Solutions AG to be Fairly Valued.
Key valuation signals for FRA:M3V:
3-Year EBITDA Growth Rate: -24.50%
GF Value™: €22.29 vs. price of €23.80 (6.8% above fair value)
No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
69GF Score
Get the complete analysis for FRA:M3V
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M3V has been successfully added to your 
